What is Pfizer Inc.'s earnings per share (EPS)?

Pfizer Inc. (PFE) reported diluted earnings per share of $1.36 for fiscal year 2025. This represents a -3.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Pfizer Inc. (PFE) Financials

PFE

Trailing 12 months to June 28, 2026

Revenue $63.7B -0.2% YoY

Net Income $4.3B -59.7% YoY

EPS (Diluted) $0.76 -59.6% YoY

Free Cash Flow $11.0B -11.7% YoY

Market Cap $161.2B as of Oct 10, 2026

Price / Sales 2.5x on $63.7B revenue, trailing 12 months to June 28, 2026

Price / Earnings 37.2x on $4.3B net income, trailing 12 months to June 28, 2026

Price / Book 1.9x on $85.2B equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 28, 2026 Reported Aug 4, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 4, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PFE SEC filings page.

Pfizer Inc. (PFE) reported $63.7B in revenue over the twelve months to Jun 28, 2026, down 0.2% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI PFE FY2025 2026-10-03

Pfizer’s earnings recovered after FY2023, but FY2025 shows a flatter business with wider gross margins and heavier leverage.

The FY2023 revenue contraction to $59.6B coincided with net margin collapsing to 3.6%, so the shock reached reported earnings, not just sales. Free-cash-flow margin also fell to 8.1% while debt-to-equity reached 0.7x, linking weaker cash generation with a more leveraged balance sheet.

Despite FY2025 revenue of $62.6B being nearly flat with FY2024, gross margin rose to 74.3%. That combination points to more profit per reported sales dollar through mix or cost structure, not top-line expansion.

Operating cash flow of $11.7B converted to free cash flow of $9.1B after investment, so the earnings recovery is supported by cash, though not dollar-for-dollar. Meanwhile, a current ratio of 1.2x alongside 0.7x debt-to-equity indicates borrowing remains meaningful even as short-term coverage is above one.

Financial Health Signals

Financial Health Score 33/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Pfizer Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Not available for Pfizer Inc., and counted as zero in the overall score.

Growth

Pfizer Inc.'s revenue declined 1.6% year-over-year, from $63.6B to $62.6B. This contraction results in a growth score of 40/100.

Leverage

Pfizer Inc. has a moderate D/E ratio of 0.71. This balance of debt and equity financing earns a leverage score of 54/100.

Liquidity

Pfizer Inc.'s current ratio of 1.16 is below the typical benchmark, resulting in a score of 27/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Cash Flow

Pfizer Inc. converts 14.5% of revenue into free cash flow ($9.1B). This strong cash generation earns a score of 75/100.

Returns

Not available for Pfizer Inc., and counted as zero in the overall score.

Piotroski F-Score Neutral

5/9

Pfizer Inc. passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality Cash-Backed

1.51x

For every $1 of reported earnings, Pfizer Inc. generates $1.51 in operating cash flow ($11.7B OCF vs $7.8B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$15.0B

YoY+2.6%

QoQ+4.0%

5Y CAGR+7.9%

10Y CAGR+1.4%

Pfizer Inc. generated $15.0B in revenue in Q2 2026. This represents an increase of 2.6% from the same quarter a year earlier. Against the prior quarter it is up 4.0%.

Net Income

-$248.0M

YoY-108.5%

QoQ-109.2%

Pfizer Inc. reported -$248.0M in net income in Q2 2026. This represents a decrease of 108.5% from the same quarter a year earlier. Against the prior quarter it is down 109.2%.

EPS (Diluted)

-$0.04

YoY-107.8%

QoQ-108.5%

Pfizer Inc. earned -$0.04 per diluted share (EPS) in Q2 2026. This represents a decrease of 107.8% from the same quarter a year earlier. Against the prior quarter it is down 108.5%.

EBITDA

Not reported for Q2 2026.

Cash & Balance Sheet

Free Cash Flow

$302.0M

YoY+125.2%

QoQ-86.1%

5Y CAGR-28.2%

10Y CAGR-24.8%

Pfizer Inc. generated $302.0M in free cash flow in Q2 2026, representing cash available after capex. This represents an increase of 125.2% from the same quarter a year earlier. Against the prior quarter it is down 86.1%.

Cash & Debt

$976.0M

YoY-40.4%

QoQ-42.7%

5Y CAGR-9.3%

10Y CAGR-11.6%

Pfizer Inc. held $976.0M in cash against $60.5B in long-term debt as of Q2 2026.

Dividends Per Share

$0.86

YoY0.0%

5Y CAGR+17.7%

10Y CAGR+12.7%

Pfizer Inc. paid $0.86 per share in dividends in Q2 2026. That is unchanged from the same quarter a year earlier.

Shares Outstanding

5.70B

YoY+0.2%

QoQ0.0%

5Y CAGR+0.5%

10Y CAGR-0.7%

Pfizer Inc. had 5.70B shares outstanding in Q2 2026. This represents an increase of 0.2% from the same quarter a year earlier. It is unchanged from the prior quarter.

Margins & Returns

Gross Margin

72.8%

YoY-1.4pp

QoQ-2.7pp

5Y change-7.7pp

10Y change-6.6pp

Pfizer Inc.'s gross margin was 72.8% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 1.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 2.7 percentage points.

Net Margin

-1.7%

YoY-21.5pp

QoQ-20.2pp

5Y change-15.9pp

10Y change-11.0pp

Pfizer Inc.'s net profit margin was -1.7% in Q2 2026, showing the share of revenue converted to profit. This is down 21.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 20.2 percentage points.

Return on Equity

-0.3%

YoY-3.6pp

QoQ-3.3pp

5Y change-2.5pp

10Y change-2.0pp

Pfizer Inc.'s ROE was -0.3% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 3.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 3.3 percentage points.

Operating Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$2.8B

YoY+13.2%

QoQ+12.8%

5Y CAGR+4.1%

10Y CAGR-1.3%

Pfizer Inc. invested $2.8B in research and development in Q2 2026. This represents an increase of 13.2% from the same quarter a year earlier. Against the prior quarter it is up 12.8%.

Capital Expenditures

$533.0M

YoY-13.8%

QoQ+22.2%

5Y CAGR+1.0%

10Y CAGR+4.2%

Pfizer Inc. invested $533.0M in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 13.8% from the same quarter a year earlier. Against the prior quarter it is up 22.2%.

Share Buybacks

Not reported for Q2 2026.

PFE Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PFE quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$63.7B	$62.6B-1.6%	$63.6B+6.8%	$59.6B-41.1%	$101.2B+24.5%	$81.3B+95.2%	$41.7B+1.8%	$40.9B+0.2%	$40.8B-22.3%	$52.5B-0.5%	$52.8B+8.1%	$48.9B-1.5%	$49.6B-3.8%	$51.6B-5.6%	$54.7B-10.4%	$61.0B
Cost of Revenue	$17.1B	$16.1B-10.0%	$17.9B-28.5%	$25.0B-27.3%	$34.3B+11.4%	$30.8B+263.3%	$8.5B+5.3%	$8.1B-10.4%	$9.0B-20.0%	$11.2B-8.9%	$12.3B+27.7%	$9.6B+0.7%	$9.6B-0.1%	$9.6B-2.4%	$9.8B-21.4%	$12.5B
Gross Profit	$46.6B	$46.5B+1.6%	$45.8B+32.3%	$34.6B-48.2%	$66.8B+32.4%	$50.5B+52.2%	$33.2B+1.0%	$32.9B+3.2%	$31.8B-22.9%	$41.3B+2.0%	$40.5B+3.3%	$39.2B-2.1%	$40.0B-4.7%	$42.0B-6.3%	$44.8B-7.6%	$48.5B
R&D Expenses	$11.1B	$10.4B-3.6%	$10.8B+1.3%	$10.7B-6.6%	$11.4B+10.3%	$10.4B+19.0%	$8.7B+3.9%	$8.4B+8.1%	$7.8B+1.0%	$7.7B-2.6%	$7.9B+2.6%	$7.7B-8.4%	$8.4B+25.7%	$6.7B-10.7%	$7.5B-13.8%	$8.7B
SG&A Expenses	$13.7B	$13.8B-6.4%	$14.7B-0.3%	$14.8B+8.0%	$13.7B+7.7%	$12.7B+9.5%	$11.6B-8.9%	$12.7B+0.9%	$12.6B-14.8%	$14.8B-0.3%	$14.8B+0.2%	$14.8B+5.1%	$14.1B-1.8%	$14.4B-5.4%	$15.2B-13.7%	$17.6B
Interest Expense	$2.7B	$2.7B-13.6%	$3.1B+39.9%	$2.2B+78.4%	$1.2B-4.1%	$1.3B-10.9%	$1.4B-7.9%	$1.6B+19.5%	$1.3B+3.6%	$1.3B+7.1%	$1.2B-1.1%	$1.2B-11.8%	$1.4B-3.8%	$1.4B-7.1%	$1.5B-9.5%	$1.7B
Income Tax	-$164.0M	-$266.0M-850.0%	-$28.0M+97.5%	-$1.1B-133.5%	$3.3B+79.7%	$1.9B+400.5%	$370.0M-36.5%	$583.0M+319.2%	-$266.0M+97.1%	-$9.0B-905.8%	$1.1B-43.6%	$2.0B-36.2%	$3.1B-27.5%	$4.3B+93.9%	$2.2B-38.7%	$3.6B
Net Income	$4.3B	$7.8B-3.2%	$8.0B+279.0%	$2.1B-93.2%	$31.4B+42.7%	$22.0B+140.0%	$9.2B-42.8%	$16.0B+43.7%	$11.2B-47.7%	$21.3B+195.3%	$7.2B+3.7%	$7.0B-23.8%	$9.1B-58.5%	$22.0B+51.0%	$14.6B+45.6%	$10.0B
EPS (Basic)	N/A	$1.37-3.5%	$1.42+273.7%	$0.38-93.2%	$5.59+42.6%	$3.92+137.6%	$1.65-42.7%	$2.88+51.6%	$1.90-46.8%	$3.57+202.5%	$1.18+4.4%	$1.13-21.5%	$1.44-55.4%	$3.23+64.8%	$1.96+53.1%	$1.28
EPS (Diluted)	$0.76	$1.36-3.5%	$1.41+281.1%	$0.37-93.2%	$5.47+42.1%	$3.85+136.2%	$1.63-42.2%	$2.82+50.8%	$1.87-46.9%	$3.52+200.9%	$1.17+5.4%	$1.11-21.8%	$1.42-55.5%	$3.19+64.4%	$1.94+52.8%	$1.27
Diluted Shares (Avg)	N/A	5.71B+0.2%	5.70B-0.2%	5.71B-0.4%	5.73B+0.4%	5.71B+1.3%	5.63B-0.8%	5.67B-5.1%	5.98B-1.3%	6.06B-1.6%	6.16B-1.6%	6.26B-2.6%	6.42B-6.8%	6.89B-8.2%	7.51B-4.6%	7.87B

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$15.0B+2.6%	$14.5B+5.4%	$17.6B-1.2%	$16.7B-5.9%	$14.7B+10.3%	$13.7B-7.8%	$17.8B+31.7%	$17.7B+36.1%
Cost of Revenue	$4.1B+8.3%	$3.5B+24.7%	$5.3B-10.8%	$4.2B-20.7%	$3.8B+14.5%	$2.8B-15.8%	$5.9B-36.2%	$5.3B+62.6%
Gross Profit	$10.9B+0.6%	$10.9B+0.3%	$12.3B+3.6%	$12.5B+0.3%	$10.9B+8.9%	$10.9B-5.5%	$11.9B+180.8%	$12.4B+27.3%
R&D Expenses	$2.8B+13.2%	$2.5B+13.0%	$3.2B+5.6%	$2.5B-2.0%	$2.5B-7.9%	$2.2B-11.6%	$3.0B+12.0%	$2.6B-1.9%
SG&A Expenses	$3.4B-0.1%	$3.0B-2.3%	$4.2B-2.6%	$3.2B-1.8%	$3.4B-8.1%	$3.0B-13.3%	$4.3B+30.3%	$3.2B-7.2%
Interest Expense	$667.0M+2.0%	$668.0M+2.1%	$711.0M-3.9%	$652.0M-16.7%	$654.0M-15.9%	$654.0M-17.2%	$740.0M+6.5%	$783.0M+54.1%
Income Tax	-$407.0M-388.7%	$461.0M+343.9%	-$2.0M+99.5%	-$216.0M-192.3%	$141.0M+205.2%	-$189.0M-164.5%	-$421.0M+56.3%	$234.0M+429.6%
Net Income	-$248.0M-108.5%	$2.7B-9.4%	-$1.6B-501.7%	$3.5B-20.7%	$2.9B+6997.6%	$3.0B-4.8%	$410.0M+117.2%	$4.5B+91.9%
EPS (Basic)	-$0.04-107.8%	$0.47-9.6%	-$0.29-514.3%	$0.62-21.5%	$0.51+5000.0%	$0.52-5.5%	$0.07+116.7%	$0.79+92.7%
EPS (Diluted)	-$0.04-107.8%	$0.47-9.6%	-$0.29-514.3%	$0.62-20.5%	$0.51+5000.0%	$0.52-5.5%	$0.07+116.7%	$0.78+90.2%
Diluted Shares (Avg)	5.70B-0.1%	5.73B+0.4%	N/A	5.71B+0.2%	5.71B+0.2%	5.71B+0.2%	N/A	5.71B-0.1%

Not reported in any period shown, so not listed: Operating Income, EBITDA.

PFE Balance Sheet

PFE quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$208.2B-2.5%	$213.4B-5.8%	$226.5B+14.9%	$197.2B+8.7%	$181.5B+17.7%	$154.2B-8.0%	$167.6B+5.1%	$159.4B-7.2%	$171.8B+0.1%	$171.6B+2.5%	$167.4B-0.1%	$167.6B-2.6%	$172.1B-7.4%	$185.8B-1.2%	$188.0B
Current Assets	$42.9B-14.8%	$50.4B+16.2%	$43.3B-15.5%	$51.3B-14.1%	$59.7B+70.2%	$35.1B+6.9%	$32.8B-34.3%	$49.9B+21.4%	$41.1B+5.6%	$38.9B-11.1%	$43.8B-21.2%	$55.6B-1.2%	$56.2B-13.2%	$64.8B+6.6%	$60.8B
Cash & Equivalents	$1.1B+9.5%	$1.0B-63.4%	$2.9B+585.8%	$416.0M-78.6%	$1.9B+8.8%	$1.8B+59.3%	$1.1B-1.6%	$1.1B-15.1%	$1.3B-48.3%	$2.6B-28.7%	$3.6B+8.9%	$3.3B+53.1%	$2.2B-78.3%	$10.1B+216.8%	$3.2B
Short-Term Investments	$9.2B-15.6%	$10.9B+147.3%	$4.4B-76.5%	$18.7B-14.9%	$22.0B+110.9%	$10.4B+22.4%	$8.5B-51.8%	$17.7B-5.1%	$18.6B+22.3%	$15.3B-22.4%	$19.6B-40.1%	$32.8B+8.4%	$30.2B+35.4%	$22.3B-4.1%	$23.3B
Inventory	$10.7B-1.8%	$10.9B+6.5%	$10.2B+13.5%	$9.0B-0.9%	$9.1B+13.0%	$8.0B+13.5%	$7.1B-5.9%	$7.5B-0.9%	$7.6B+11.7%	$6.8B-9.7%	$7.5B+32.7%	$5.7B-8.2%	$6.2B+1.5%	$6.1B-8.1%	$6.6B
Accounts Receivable	$11.9B+3.6%	$11.5B-0.9%	$11.6B+5.6%	$11.0B-4.6%	$11.5B+45.1%	$7.9B+16.8%	$6.8B-15.6%	$8.0B-2.4%	$8.2B0.0%	$8.2B+0.6%	$8.2B-2.7%	$8.4B-10.2%	$9.4B-12.3%	$10.7B-18.2%	$13.1B
Long-Term Investments	$1.0M	$0-100.0%	$150.0M-57.4%	$352.0M-32.4%	$521.0M+307.0%	$128.0M-59.4%	$315.0M-35.8%	$491.0M-90.4%	$5.1B-15.9%	$6.0B-62.2%	$16.0B-8.7%	$17.5B+6.8%	$16.4B+16.0%	$14.1B+44.2%	$9.8B
Goodwill	$71.3B+4.0%	$68.5B+1.1%	$67.8B+31.9%	$51.4B+4.4%	$49.2B-0.7%	$49.6B+2.9%	$48.2B+12.2%	$42.9B-23.3%	$56.0B+2.8%	$54.4B+12.9%	$48.2B+14.7%	$42.1B-1.1%	$42.5B-2.6%	$43.7B-2.0%	$44.6B
Total Liabilities	$121.4B-2.8%	$124.9B-9.0%	$137.2B+35.5%	$101.3B-2.6%	$104.0B+14.6%	$90.8B-12.9%	$104.1B+8.9%	$95.7B-4.5%	$100.1B-10.4%	$111.8B+9.2%	$102.4B+6.7%	$95.9B+0.5%	$95.5B-8.3%	$104.1B-1.2%	$105.4B
Current Liabilities	$37.0B-14.0%	$43.0B-10.0%	$47.8B+13.4%	$42.1B-1.2%	$42.7B+64.6%	$25.9B-30.5%	$37.3B+17.1%	$31.9B+4.7%	$30.4B-2.2%	$31.1B+5.8%	$29.4B+36.2%	$21.6B-7.6%	$23.4B-19.9%	$29.2B+1.0%	$28.9B
Non-Current Liabilities	$84.4B+3.0%	$81.9B-8.4%	$89.4B+51.2%	$59.1B-3.6%	$61.3B-5.4%	$64.8B-3.0%	$66.8B+4.8%	$63.8B-8.5%	$69.7B-13.6%	$80.7B+10.5%	$73.0B-1.8%	$74.4B+3.1%	$72.1B-3.8%	$74.9B-2.0%	$76.5B
Long-Term Debt	$61.6B+7.4%	$57.4B-6.7%	$61.5B+87.1%	$32.9B-9.1%	$36.2B-2.5%	$37.1B+3.3%	$36.0B+9.3%	$32.9B-1.9%	$33.5B+6.8%	$31.4B+9.2%	$28.7B-8.9%	$31.5B+3.5%	$30.5B-1.8%	$31.0B-11.1%	$34.9B
Total Equity	$86.5B-2.0%	$88.2B-0.9%	$89.0B-6.9%	$95.7B+23.9%	$77.2B+22.1%	$63.2B+0.2%	$63.1B-0.4%	$63.4B-11.1%	$71.3B+19.8%	$59.5B-8.0%	$64.7B-9.2%	$71.3B-6.6%	$76.3B-6.1%	$81.3B-1.1%	$82.2B
Retained Earnings	$114.6B-1.8%	$116.7B-1.4%	$118.4B-5.8%	$125.7B+21.5%	$103.4B+14.4%	$90.4B-7.5%	$97.7B+9.1%	$89.6B+5.0%	$85.3B+18.8%	$71.8B-0.3%	$72.0B-0.3%	$72.2B+3.5%	$69.7B+28.6%	$54.2B+17.4%	$46.2B

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$201.1B-2.4%	$207.6B-0.2%	$208.2B-2.5%	$208.7B-4.9%	$206.1B-4.7%	$208.0B-5.9%	$213.4B-0.8%	$219.5B-0.3%
Current Assets	$41.4B-5.4%	$42.8B-6.6%	$42.9B-14.8%	$46.9B+8.6%	$43.7B+15.5%	$45.9B+8.1%	$50.4B-32.0%	$43.2B-41.1%
Cash & Equivalents	$976.0M-40.4%	$1.7B+19.1%	$1.1B+9.5%	$1.3B+23.0%	$1.6B+55.7%	$1.4B+98.9%	$1.0B-66.9%	$1.1B-58.5%
Short-Term Investments	$7.3B-23.6%	$8.2B-41.3%	$9.2B-15.6%	$10.1B+47.8%	$9.5B+116.4%	$14.0B+69.8%	$10.9B-58.5%	$6.8B-71.6%
Inventory	$9.9B-14.8%	$10.7B-1.7%	$10.7B-1.8%	$11.5B-2.2%	$11.7B+1.9%	$10.9B-0.4%	$10.9B+6.3%	$11.7B+13.7%
Accounts Receivable	$12.5B+3.4%	$12.6B+6.2%	$11.9B+3.6%	$14.3B-1.3%	$12.1B+6.0%	$11.8B+7.8%	$11.5B+3.4%	$14.5B+41.2%
Long-Term Investments	$0-100.0%	$0-100.0%	$1.0M	$1.0M-83.3%	$1.0M-98.6%	$47.0M-65.7%	$0-100.0%	$6.0M-97.6%
Goodwill	$71.4B+3.5%	$71.4B+4.3%	$71.3B+4.0%	$69.1B+0.8%	$69.0B+0.8%	$68.4B-1.2%	$68.5B+33.0%	$68.6B+33.0%
Total Liabilities	$115.6B-1.2%	$117.2B-0.2%	$121.4B-2.8%	$115.6B-8.9%	$117.1B-8.7%	$117.4B-8.7%	$124.9B+6.0%	$126.9B+5.0%
Current Liabilities	$32.6B-13.5%	$34.3B-5.8%	$37.0B-14.0%	$36.6B-15.3%	$37.7B-13.9%	$36.5B-10.0%	$43.0B+38.1%	$43.2B+24.7%
Non-Current Liabilities	$83.0B+4.6%	$82.9B+2.4%	$84.4B+3.0%	$79.0B-5.6%	$79.4B-6.0%	$80.9B-8.1%	$81.9B-5.5%	$83.7B-2.9%
Long-Term Debt	$60.5B+5.2%	$60.6B+5.1%	$61.6B+7.4%	$57.4B-1.0%	$57.5B0.0%	$57.6B-6.0%	$57.4B-6.0%	$58.0B-5.5%
Total Equity	$85.2B-4.0%	$90.1B-0.3%	$86.5B-2.0%	$92.8B+0.6%	$88.7B+1.1%	$90.3B-2.1%	$88.2B-9.0%	$92.3B-6.8%
Retained Earnings	$112.1B-4.7%	$117.2B-2.0%	$114.6B-1.8%	$121.2B+0.1%	$117.6B+0.9%	$119.6B-1.4%	$116.7B-7.7%	$121.1B-6.0%

PFE Cash Flow Statement

PFE quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$13.4B	$11.7B-8.2%	$12.7B+46.5%	$8.7B-70.3%	$29.3B-10.2%	$32.6B+126.2%	$14.4B+14.4%	$12.6B-20.5%	$15.8B-5.8%	$16.8B+3.8%	$16.2B+10.2%	$14.7B-14.0%	$17.1B-3.4%	$17.7B+5.6%	$16.7B-17.3%	$20.2B
Depreciation & Amortization	N/A	$6.6B-6.0%	$7.0B+11.5%	$6.3B+24.2%	$5.1B-2.4%	$5.2B+10.9%	$4.7B-18.7%	$5.8B-9.9%	$6.4B+1.8%	$6.3B+8.9%	$5.8B+11.6%	$5.2B-6.9%	$5.5B-12.2%	$6.3B-14.7%	$7.4B-15.0%	$8.7B
Stock-Based Compensation	N/A	$799.0M-8.9%	$877.0M+67.0%	$525.0M-39.8%	$872.0M-26.2%	$1.2B+56.6%	$755.0M+9.9%	$687.0M-25.6%	$923.0M+9.9%	$840.0M+21.6%	$691.0M+3.3%	$669.0M+14.2%	$586.0M+12.0%	$523.0M+8.7%	$481.0M+14.8%	$419.0M
Capital Expenditures	$2.4B	$2.6B-9.6%	$2.9B-25.5%	$3.9B+20.7%	$3.2B+19.4%	$2.7B+21.8%	$2.2B+8.8%	$2.0B+3.1%	$2.0B+1.4%	$2.0B+7.3%	$1.8B+30.5%	$1.4B+16.5%	$1.2B-0.6%	$1.2B-9.1%	$1.3B-20.1%	$1.7B
Free Cash Flow	$11.0B	$9.1B-7.7%	$9.8B+105.2%	$4.8B-81.6%	$26.0B-12.8%	$29.9B+145.3%	$12.2B+15.5%	$10.5B-23.8%	$13.8B-6.8%	$14.8B+3.3%	$14.4B+8.1%	$13.3B-16.3%	$15.9B-3.6%	$16.5B+6.9%	$15.4B-17.0%	$18.6B
Investing Cash Flow	-$5.7B	-$1.4B-150.9%	$2.7B+108.2%	-$32.3B-104.5%	-$15.8B+30.0%	-$22.5B-427.9%	-$4.3B-8.3%	-$3.9B-187.2%	$4.5B+195.5%	-$4.7B+39.2%	-$7.8B-161.4%	-$3.0B+47.3%	-$5.7B+46.4%	-$10.5B-271.3%	$6.2B+233.9%	$1.8B
Financing Cash Flow	-$8.4B	-$10.3B+39.9%	-$17.1B-165.8%	$26.1B+275.7%	-$14.8B-51.1%	-$9.8B-1.7%	-$9.6B-13.7%	-$8.5B+58.5%	-$20.4B-53.1%	-$13.3B-44.7%	-$9.2B+11.3%	-$10.4B-2.2%	-$10.2B+32.0%	-$15.0B+6.4%	-$16.0B+22.4%	-$20.6B
Share Buybacks	N/A	N/A	$0	$0-100.0%	$2.0B	$0	$0-100.0%	$8.9B-27.3%	$12.2B+144.0%	$5.0B0.0%	$5.0B-18.8%	$6.2B+23.2%	$5.0B-69.3%	$16.3B+98.0%	$8.2B-8.6%	$9.0B

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	$835.0M+243.5%	$2.6B+12.0%	$5.3B-20.4%	$4.6B-31.4%	-$582.0M+67.3%	$2.3B+114.2%	$6.7B+94.5%	$6.7B+655.8%
Depreciation & Amortization	$1.6B-0.2%	$1.6B-0.3%	$1.7B-5.8%	$1.7B-5.3%	$1.6B-6.1%	$1.6B-6.8%	$1.8B+14.8%	$1.8B+11.6%
Stock-Based Compensation	N/A	$272.0M+60.0%	N/A	N/A	N/A	$170.0M-22.7%	N/A	N/A
Capital Expenditures	$533.0M-13.8%	$436.0M-22.7%	$845.0M-7.9%	$602.0M-7.5%	$618.0M-3.0%	$564.0M-19.9%	$917.0M+13.2%	$651.0M-28.8%
Free Cash Flow	$302.0M+125.2%	$2.2B+23.0%	$4.5B-22.4%	$4.0B-34.0%	-$1.2B+50.4%	$1.8B+358.8%	$5.8B+119.3%	$6.1B+385.7%
Investing Cash Flow	$2.1B-46.7%	$785.0M-76.0%	-$6.1B-278.7%	-$2.4B-18.1%	$4.0B-14.1%	$3.3B+89.0%	-$1.6B-282.8%	-$2.1B+91.9%
Financing Cash Flow	-$3.7B-14.6%	-$2.9B+45.4%	$596.0M+111.7%	-$2.5B+46.6%	-$3.2B-30.0%	-$5.2B-6.0%	-$5.1B-35.3%	-$4.6B-117.1%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

PFE Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PFE quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	74.3%+2.4pp	71.9%+13.8pp	58.1%-8.0pp	66.0%+4.0pp	62.1%-17.5pp	79.6%-0.7pp	80.3%+2.3pp	78.0%-0.6pp	78.6%+2.0pp	76.7%-3.6pp	80.3%-0.4pp	80.7%-0.7pp	81.4%-0.6pp	82.0%+2.5pp	79.5%
Net Margin	12.4%-0.2pp	12.6%+9.1pp	3.6%-27.4pp	31.0%+4.0pp	27.0%+5.0pp	22.0%-17.2pp	39.2%+11.9pp	27.3%-13.2pp	40.6%+26.9pp	13.7%-0.6pp	14.2%-4.2pp	18.4%-24.2pp	42.6%+16.0pp	26.7%+10.3pp	16.4%
Return on Equity	9.0%-0.1pp	9.1%+6.7pp	2.4%-30.4pp	32.8%+4.3pp	28.5%+14.0pp	14.5%-10.9pp	25.4%+7.8pp	17.6%-12.3pp	29.9%+17.8pp	12.1%+1.4pp	10.8%-2.1pp	12.8%-16.0pp	28.8%+10.9pp	17.9%+5.7pp	12.2%
Return on Assets	3.7%0.0pp	3.8%+2.8pp	0.9%-15.0pp	15.9%+3.8pp	12.1%+6.2pp	5.9%-3.6pp	9.6%+2.6pp	7.0%-5.4pp	12.4%+8.2pp	4.2%0.0pp	4.2%-1.3pp	5.5%-7.3pp	12.8%+4.9pp	7.8%+2.5pp	5.3%
Current Ratio	1.160.0x	1.17+0.3x	0.91-0.3x	1.22-0.2x	1.400.0x	1.35+0.5x	0.88-0.7x	1.57+0.2x	1.35+0.1x	1.25-0.2x	1.49-1.1x	2.58+0.2x	2.41+0.2x	2.22+0.1x	2.10
Debt-to-Equity	0.71+0.1x	0.650.0x	0.69+0.3x	0.34-0.1x	0.47-0.1x	0.590.0x	0.57+0.1x	0.520.0x	0.47-0.1x	0.53+0.1x	0.440.0x	0.440.0x	0.400.0x	0.380.0x	0.42
Asset Turnover	0.300.0x	0.300.0x	0.26-0.3x	0.51+0.1x	0.45+0.2x	0.270.0x	0.240.0x	0.260.0x	0.310.0x	0.310.0x	0.290.0x	0.300.0x	0.300.0x	0.290.0x	0.32
FCF Margin	14.5%-1.0pp	15.5%+7.4pp	8.1%-17.7pp	25.7%-11.0pp	36.7%+7.5pp	29.2%+3.5pp	25.8%-8.1pp	33.9%+5.7pp	28.2%+1.0pp	27.2%0.0pp	27.2%-4.8pp	32.0%+0.1pp	31.9%+3.7pp	28.2%-2.2pp	30.4%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	72.8%-1.4pp	75.4%-3.8pp	70.0%+3.2pp	75.0%+4.7pp	74.2%-0.9pp	79.3%+2.0pp	66.7%+35.4pp	70.3%-4.8pp
Net Margin	-1.7%-21.5pp	18.6%-3.0pp	-9.4%-11.7pp	21.3%-4.0pp	19.9%+19.6pp	21.6%+0.7pp	2.3%+20.0pp	25.2%+7.3pp
Return on Equity	-0.3%-3.6pp	3.0%-0.3pp	-1.9%-2.4pp	3.8%-1.0pp	3.3%+3.2pp	3.3%-0.1pp	0.5%+2.9pp	4.8%+2.5pp
Return on Assets	-0.1%-1.5pp	1.3%-0.1pp	-0.8%-1.0pp	1.7%-0.3pp	1.4%+1.4pp	1.4%0.0pp	0.2%+1.3pp	2.0%+1.0pp
Current Ratio	1.27+0.1x	1.250.0x	1.160.0x	1.28+0.3x	1.16+0.3x	1.26+0.2x	1.17-1.2x	1.00-1.1x
Debt-to-Equity	0.71+0.1x	0.670.0x	0.71+0.1x	0.620.0x	0.650.0x	0.640.0x	0.650.0x	0.630.0x
Asset Turnover	0.070.0x	0.070.0x	0.080.0x	0.080.0x	0.070.0x	0.070.0x	0.080.0x	0.080.0x
FCF Margin	2.0%+10.2pp	15.1%+2.2pp	25.7%-7.0pp	24.0%-10.2pp	-8.2%+10.0pp	12.9%+10.3pp	32.7%+13.1pp	34.3%+50.6pp

Not reported in any period shown, so not listed: Operating Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Pfizer Inc. PFE	FY2025	$62.6B	$7.8B	12.4%	$161.2B	33/100
Gilead Sciences Inc GILD	FY2025	$29.4B	$8.5B	28.9%	$187.4B	64/100
Amgen Inc AMGN	FY2025	$36.8B	$7.7B	21.0%	$224.3B	63/100
Bristol-Myers Squibb Co. BMY	FY2025	$48.2B	$7.1B	14.6%	$120.8B	33/100

Where Pfizer Inc. Ranks

Frequently Asked Questions

What is Pfizer Inc.'s annual revenue?

Pfizer Inc. (PFE) reported $62.6B in total revenue for fiscal year 2025. This represents a -1.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Pfizer Inc.'s revenue growing?

Pfizer Inc. (PFE) revenue declined by 1.6% year-over-year, from $63.6B to $62.6B in fiscal year 2025.

Is Pfizer Inc. profitable?

Yes, Pfizer Inc. (PFE) reported a net income of $7.8B in fiscal year 2025, with a net profit margin of 12.4%.

How much debt does Pfizer Inc. have?

As of fiscal year 2025, Pfizer Inc. (PFE) had $1.1B in cash and equivalents against $61.6B in long-term debt.

What is Pfizer Inc.'s gross margin?

Pfizer Inc. (PFE) had a gross margin of 74.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Pfizer Inc.'s net profit margin?

Pfizer Inc. (PFE) had a net profit margin of 12.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Does Pfizer Inc. pay dividends?

Yes, Pfizer Inc. (PFE) paid $1.72 per share in dividends during fiscal year 2025.

What is Pfizer Inc.'s return on equity (ROE)?

Pfizer Inc. (PFE) has a return on equity of 9.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Pfizer Inc.'s free cash flow?

Pfizer Inc. (PFE) generated $9.1B in free cash flow during fiscal year 2025. This represents a -7.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Pfizer Inc.'s operating cash flow?

Pfizer Inc. (PFE) generated $11.7B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Pfizer Inc.'s total assets?

Pfizer Inc. (PFE) had $208.2B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Pfizer Inc.'s capital expenditures?

Pfizer Inc. (PFE) invested $2.6B in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Pfizer Inc. spend on research and development?

Pfizer Inc. (PFE) invested $10.4B in research and development during fiscal year 2025.

How many shares does Pfizer Inc. have outstanding?

Pfizer Inc. (PFE) had 5.69B shares outstanding as of fiscal year 2025.

What is Pfizer Inc.'s current ratio?

Pfizer Inc. (PFE) had a current ratio of 1.16 as of fiscal year 2025, which is considered adequate.

What is Pfizer Inc.'s debt-to-equity ratio?

Pfizer Inc. (PFE) had a debt-to-equity ratio of 0.71 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Pfizer Inc.'s return on assets (ROA)?

Pfizer Inc. (PFE) had a return on assets of 3.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Pfizer Inc.'s P/E ratio?

Pfizer Inc. (PFE) trades at 37.2x earnings, its market capitalization divided by net income of $4.3B net income, trailing 12 months to June 28, 2026. The market capitalization is $161.2B as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Pfizer Inc.'s price-to-sales ratio?

Pfizer Inc. (PFE) trades at 2.5x sales, its market capitalization divided by revenue of $63.7B revenue, trailing 12 months to June 28, 2026. The market capitalization is $161.2B as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Pfizer Inc.'s Piotroski F-Score?

Pfizer Inc. (PFE) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Pfizer Inc.'s earnings high quality?

Pfizer Inc. (PFE) has an earnings quality ratio of 1.51x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Pfizer Inc.?

Pfizer Inc. (PFE) scores 33 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.